Artificial Neural Network for Compositional Ionic Liquid Viscosity Prediction

Being a new generation of green solvents and high-tech reaction media of the future, ionic liquids have increasingly attracted much attention. Of particular interest in this context are room temperature ionic liquids (in short as ILs in this paper). Due to the relatively high viscosity, ILs is expected to be used in the form of solvent diluted mixture with reduced viscosity in industrial application, where predicting the viscosity of IL mixture has been an important research issue. Different IL mixture and many modelling approaches have been investigated. The objective of this study is to provide an alternative model approach using soft computing technique, i.e., artificial neural network (ANN) model, to predict the compositional viscosity of binary mixtures of ILs [C _n-mim][NTf ₂] with n=4, 6, 8, 10 in methanol and ethanol over the entire range of molar fraction at a broad range of temperatures from T=293.0-328.0K. The results show that the proposed ANN model provides alternative way to predict compositional viscosity successfully with highly improved accuracy and also show its potential to be extensively utilized to predict compositional viscosity taking account of IL alkyl chain length, as well as temperature and compositions simultaneously, i.e., more complex intermolecular interactions between components in which it would be hard or impossible to establish the analytical model. This illustrates the potential application of ANN in the case that the physical and thermodynamic properties are highly non-linear or too complex. © 2012 Copyright the authors.

Artificial neural network model to predict compositional viscosity over a broad range of temperatures

The objective of this study is to provide an alternative model approach, i.e., artificial neural network (ANN) model, to predict the compositional viscosity of binary mixtures of room temperature ionic liquids (in short as ILs) [C _n-mim] [NTf ₂] with n=4, 6, 8, 10 in methanol and ethanol over the entire range of molar fraction at a broad range of temperatures from T=293.0328.0K. The results show that the proposed ANN model provides alternative way to predict compositional viscosity successfully with highly improved accuracy and also show its potential to be extensively utilized to predict compositional viscosity over a wide range of temperatures and more complex viscosity compositions, i.e., more complex intermolecular interactions between components in which it would be hard or impossible to establish the analytical model. © 2010 IEEE.

Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors

We have evaluated the effect of in vivo Campath-1G on engraftment and GVHD in 23 patients with severe aplastic anaemia transplanted from HLA-identical sibling donors. In 14 patients Campath 1g was given pre-transplant for up to 9 days in an attempt to overcome graft rejection (group 1). In nine patients Campath-1G was given pre-transplant, but also continued post-transplant until day +5 to reduce GVHD (group 2). There were three patients with late graft failure in group I following initial neutrophil engraftment, and four cases of grade II+ GVHD. In group II, two patients had early graft failure (no take), and there were no cases of acute GVHD out of seven evaluable patients. One patient in group I developed chronic GVHD of the liver, and two patients (one in each group) had transient localised chronic GVHD. PCR of short tandem repeats was used to evaluate chimaeric status in 13 patients. Of 11 patients with initial neutrophil engraftment, only one had 100% donor haemopoiesis at all times. The remaining patients had either transient mixed chimaerism or persistence of recipient (< 20%) cells. We conclude that in vivo Campath-1G is associated with a high incidence of mixed chimaerism which tips the balance away from GVHD but towards graft rejection.

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

BACKGROUND: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control.

METHODS: Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75,000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights.

FINDINGS: 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease.

INTERPRETATION: International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems.